IHS Chemical Week

Regions :: North America :: U.S.

Roche to buy US biotech firm InterMune for $8.3 billion

11:21 AM MDT | August 24, 2014 | Natasha Alperowicz

Roche (Basel) said today that it has agreed to acquire InterMune (Brisbane, CA), a biotech company focused on R&D and commercializing therapies in pulmonology and orphan fibrotic diseases, for $8.3 billion. The offer represents a premium of 38% to InterMune’s closing price on 22 August and a premium of 63% to InterMune’s unaffected closing price on 12 August. Both companies' boards have approved the agreement. The transaction is expected to close this year.   Roche, under the terms of the agreement, will commence a tender offer by 29 August...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa